SUNNYVALE, Calif., Aug. 27, 2013 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS) a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis, today announced the publication of two new independent peer-reviewed publications on its patented biologic MANF. The publications from research groups in Europe and Asia focused on furthering the scientific community's understanding of how MANF is upregulated and secreted in models of cell biology and orphan diseases.
Help employers find you! Check out all the jobs and post your resume.
